Publications by authors named "Joseph A Sutton"
Background: The LRT trial (Low-Risk Transcatheter Aortic Valve Replacement [TAVR]) demonstrated the safety and feasibility of TAVR in low-risk patients, with excellent 1- and 2-year outcomes. The objective of the current study is to provide the overall clinical outcomes and the impact of 30-day hypoattenuated leaflet thickening (HALT) on structural valve deterioration at 4 years.
Methods: The prospective, multicenter LRT trial was the first Food and Drug Administration-approved investigational device exemption study to evaluate feasibility and safety of TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis.
Background: Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay regimen for acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI). We aimed to investigate DAPT compliance and switching patterns in ACS patients prescribed ticagrelor and aspirin. Secondly, we evaluated the impact of a pilot strategy of close surveillance telephone calls.
View Article and Find Full Text PDFMitral valve disease is insidious and associated with a decreased quality of life and survival over time. Despite surgery being the standard of care, many patients are at prohibitive surgical risk. Furthermore, a substantial proportion of patients with symptomatic mitral valve disease fail stringent screening criteria for transcatheter mitral valve replacement (TMVR).
View Article and Find Full Text PDFArticle Synopsis
- The Mayo-Baylor RIGHT 10K Study focused on using pharmacogenomics to improve drug prescriptions based on genetic information in a large population.
- Researchers sequenced the DNA of over 10,000 participants to identify genetic variations affecting drug responses, and integrated these findings into electronic health records.
- Results showed that 79% of participants had actionable genetic variants affecting their medication, highlighting the need for a proactive approach to personalized medicine in clinical care.
Prosthetic valve endocarditis after transcatheter aortic valve replacement in low-risk patients.
Catheter Cardiovasc Interv
February 2022
Objectives: We sought to report details of the incidence, organisms, clinical course, and outcomes of prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement (TAVR) in low-risk patients.
Background: PVE remains a rare but devastating complication of aortic valve replacement. Data regarding PVE after TAVR in low-risk patients are lacking.
Article Synopsis
- Pharmacogenomics (PGx) clinical decision support in electronic health records (EHR) aims to help doctors provide personalized treatment based on genetic information, but there are several challenges in implementation.
- Traditional EHR systems have been criticized for not being equipped to handle the complexities of precision medicine, leading to difficulties for clinicians.
- The authors discuss their implementation of a new EHR feature, the Genomic Indicators repository, which enhances PGx data management and includes educational resources to improve clinician awareness and support.
Clinical use of pharmacogenomic (PGx) knowledge at the bedside is new and complex. Our program has implemented multiple PGx-CDS interventions in different clinical settings and in multiple commercial EHRs. Herein, we discuss lessons learned and propose general technical guidelines related to PGx implementation.
View Article and Find Full Text PDF